Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
NCT07213466 on ClinicalTrials.gov · last registry update 2026-03-11
Recruiting now, toward 100 participants. Due to report 1 February 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Mayo Clinic
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2026-01-19
- Primary completion
- 2028-02-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population.
Conditions studied
Bipolar I Disorder · Bipolar II Disorder · Schizo Affective Disorder · Obesity · Weight Loss · GLP - 1
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.